Between 1982 and 2009 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers. Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. The mean age in the two groups at transplantation was 46±12 and 55 ± 8 years, respectively (Po0.001). When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (P ¼ 0.003). Among the RIC patients, the survival was significantly (P ¼ 0.003) better for the patients with age o60 years (a 10-year survival close to 80%) than for the older patients. The type of stem cell donor did not significantly affect the survival. No significant difference was found in TRM at 100 days between the MAC-and the RIC-treated patients. The probability of survival at 5 years was 49% for the MAC-treated patients and 59% in the RIC group (P ¼ 0.125). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (Po0.001). The OS at 5 years was 70, 59 and 41% for patients with Lille score 0, 1 and 2, respectively (P ¼ 0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MAC-treated patients (Po0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups. Our conclusions are (1) allo-SCT performed with RIC gives a better survival compared with MAC. (2) age over 60 years is strongly related to a worse outcome and (3) patients with higher Lille score had a shorter survival.
Introduction
The myeloproliferative neoplasms (MPN) comprise the well-defined entities polycythemia vera (PV), essential trombocythemia (ET) and primary myelofibrosis (PMF). These three entities have several similar features. Thrombocytosis is frequently found in the chronic phase of the three diseases, 1 and an acquired mutation in the tyrosine kinase domain of the JAK2 gene can be detected in all types of MPNs, although in different frequencies. 2 Both ET and PV can acquire BM fibrosis over time, 3 and thereby transform to MF, which cannot be distinguished by morphology or clinical variables from de novo PMF. 4 PMF is a clonal myeloproliferative disorder arising from the neoplastic transformation of early hematopoietic progenitor cells. 5 It is a chronic disorder characterized by anemia, BM fibrosis, extramedullary hematopoiesis, leukoerythroblastosis and hepatosplenomegaly. 6 The disease primarily affects the elderly, with a median age, at diagnosis, of 67 years in one study 7 and 75 years in another. 8 Several prognostic scores have been published. The 'Lille score' was the most commonly used at the time of study design and includes Hb (o10 g/dL) and WBC counts (o4 or 430 Â 10 9 /L). This score classifies patients into a 'low-risk' group (score 0), with a median survival of 93 months, an 'intermediate group' (score 1), with median survival of 26 months and a 'high-risk' group (score 2), with a median survival of 13 months. 9 Factors associated with a poorer prognosis include age 460 years, weight loss, Hb o10 g/dL, WBC o4 or 430 Â 10 9 /L and peripheral blasts. 10 Patients with PMF suffer a risk of more than 1% per year of developing AML with poor prognosis. 11 The majority of patients can only be offered supportive treatment, which may improve anemia, alleviate constitutional symptoms and splenomegaly, and may temporarily decrease the fibrosis content in the BM. However, potentially curative therapy can be offered to the younger MF patients with allo-HSCT. Survival rates between 40 and 60% after myeloablative conditioning (MAC) SCT of MF patients have been reported by several groups. 12 However, most groups have restricted this therapy to patients o50-54 years of age. During the last decade, reduced intensity conditioning (RIC) allo-SCT has been increasingly used, making it possible to treat elderly patient with survival rates comparable to those of younger patients treated with conventional SCT. 13 The Swedish MPD Study Group reported the Swedish MF SCT experience during the period 1982-2004. 7 The aim of the present study was to report all patients with MF in chronic phase treated with allo-MAC SCT and allo-RIC SCT from the six Swedish, the one Danish, the one Norwegian and one of two Finnish transplant centers. The aim was to study survival rates, the need for donor lymphocyte infusion (DLI), the rate of GVHD, TRM and the complication frequency after MAC and RIC transplantations for MF.
Patients and methods
Between 1982 and 2009, 92 patients with MF in chronic phase underwent allo-SCT at nine transplant centers in the Nordic countries, and 100% of transplanted patients were included. Out of these patients, 70 had PMF, whereas 22 had been diagnosed earlier with another MPN, which had transformed into MF (9 with ET, 12 with PV and 1 with MPN unclassified). The majority of the patients (76 out of 92) were transplanted between 2000 and 2009. In total, 64 patients were transplanted at six centers in Sweden; 21 at Karolinska UH Huddinge, 15 at Akademiska UH Uppsala, 13 at Sahlgrenska UH Go¨teborg, 6 at Norrlands UH Umea˚, 5 at Lunds UH and 4 at RH Linko¨ping. A total of 12 patients were transplanted at Turku UH, one of the two transplant centers in Finland. In total, 10 were transplanted in Denmark, at Rigshospitalet, UH Copenhagen. In Norway, six patients were transplanted at Rikshospitalet, Oslo. A total of 58 patients were male and 34 were female. Overall, 40 patients were treated with MAC and 52 were given RIC. Another seven patients with MPN were reported to the European group for blood and marrow transplantation (EBMT) registry database. They were excluded from this study because of AML transformation (n ¼ 3), or PV/ET without MF (n ¼ 4). The mean age for the patients in the MAC group was 46 ± 12 years (range 5-63 years), and the mean age for the RIC patients was 55±8 (range 22-66) ( Table 1) .
The majority of patients (41/52) treated with RIC had a regimen based on busulfan and fludarabine, and in addition most often antithymocyteglobulin (ATG). Some patients were treated with fludarabine as a single drug and some in combination with melphalan. In the MAC group, cyclophosphamide-based regimens were used in 30 of the 40 cases, often in combination with busulfan or TBI.
The clinical data were collected from the EBMT registry database.
14 Data regarding initial type of MPN, time of diagnosis, Lille score, type of conditioning, type of donor, complications, aGVHD and cause of death were well documented. Other relevant data, such as spleen size, chromosomal aberrations, reason for transplantation, cGVHD and Karnovsky index were not evaluable in several patients.
The main indications for transplantation were 'high-risk' MF, symptomatic MF, anemia, thrombocytopenia and/or constitutional symptoms.
The median time from MPN diagnosis to transplantation for the patients that received MAC treatment was 39±46 (range ) months compared with 79 ± 102 (range 4-458) months for the group who received RIC. This difference can partly be explained by the fact that more patients in the RIC group had a post-PV/ET MF (Table 1) .
Data for the evaluation of the risk according to Lille score 9 were available either at diagnosis or at transplantation for 90 patients. Overall, 18 patients had score 0, 41 had score 1 and 31 had score 2 ( Table 1) . International Working Group score 15 could be calculated for 72 of the patients; 16 had score 0, 32 had score 1, 23 had score 2 and 1 patient had score 3 ( Table 1 ).
The majority of the patients (75 out of 92) received PBSC. Bone marrow was the stem cell source for 14 of the patients, all of whom were treated with MAC. In addition, three patients received a combination of PBSC and BM. Cytogenetic analyses were evaluable in 39 patients, and clonal cytogenetic abnormalities were identified in 22 cases 
Results

Age at transplantation
The mean age at transplantation for the MAC-treated patients was 46±12 years (range 5-63 years) compared with 55±8 (range 22-66 years) for the patients in the RIC group (Po0.001). The time from MPN diagnosis to transplantation was significantly longer for the RIC patients, 79±102 months compared with 39±46 months in the MAC group (P ¼ 0.027).
Engraftment
Neutrophil engraftment (i.e., neutrophils exceeding 0.5 Â 10 9 /L for 3 days) was reported for 79 of the 92 patients (86%). There was no significant difference between the MAC and the RIC group, the median time for the two groups being 19 days (mean 22±17 (range 12-106) and 21 ± 10 days (range 0-54), respectively). With regard to platelet recovery, two different limits are used in the EBMT registry, time to 420 Â 10 9 /L or 450 Â 10 9 /L without transfusion. In the majority of patients (76%) 420 Â 10 9 /L was reported, and these data were therefore used for the calculations. For the MAC group, the median time to platelet recovery was 24 days (range, 7 to greater than 100), and 2 patients did not reach 420 Â 10 9 /L. In the RICtransplanted patients the median time to platelet recovery was 18.5 days (range 0-135), one patient never reached 420 Â 10 9 /L and two patients never had values below this value. The difference between the two groups did not reach statistical significance.
Complications
Early procedure-related complications (within 100 days from transplantation) were common. Out of 52, 41 patients in the RIC-transplanted group were evaluable for early complications. Out of these 41 patients, 13 were reported to have had no or minor complications, whereas 25 had infectious disease, mostly bacterial or viral. Only two patients were reported to have major bleeding and one had progressive disease.
Only 5 of the evaluable 29 (out of 40) transplanted patients in the MAC group had no or minor complications. Eighteen of the patients had bacterial or viral infections.
Six patients had major bleedings, and one had progressive disease (progressive MF or transformation into acute leukemia). Six patients had organ failure, including multiorgan failure, acute respiratory distress syndrome, cardiac and renal impairment. Complications reported after the first 3 months after transplantation were relatively few. Major bleeding occurred in five patients, progressive disease or transformation into AML in seven patients. Four cases of unrelated malignancy were diagnosed after the early post-transplantation period. Details are shown in Table 2 .
GVHD
In the EBMT records, GVHD is frequently registered at 3 months after transplantation. In the MAC group, data from 29 of the 40 patients are available. Seven patients had no sign of acute GVHD, 12 patients had grade I, 7 patients had grade II and 3 patients had grade III-IV. For the RICtreated group, GVHD status for 46 out of the 52 patients was available: 33 had no GVHD, 6 had grade I, 2 had grade II and 5 had grade III-IV. The difference between the two groups was statistically significant (Po0.001). The most frequent organ affected in both groups was the skin. Also, liver and gastrointestinal engagement was reported, however, in lower frequency.
Survival
The TRM at 100 days from transplantation was 17.5% for the patients treated with MAC compared with 5.8% for the RIC-treated patients. This difference did not reach statistical significance (P ¼ 0.096).
The probability of OS at 5 years for the group of transplanted patients who received MAC was 49% compared with 59% in the RIC group, with adjustment for differences in age RIC treatment was found superior (hazard ratio was 3.58 with 95% confidence interval 1.54-8.28, P ¼ 0.003) (Table 3, Figure 1 ). Further, if the treatment groups were divided with respect to age at transplantation, that is, under or over the overall median age (53 years), the survival difference was statistically significant (P ¼ 0.003). Probability of OS at 5-years posttransplantation for RIC patients, with age below 53 were no significant differences between the MAC and RIC groups with respect to Lille score, time from diagnosis to transplantation or initial diagnosis. The 52 patients treated with RIC were divided into three groups with respect to age: o50 years (n ¼ 9), 51-60 years (n ¼ 25) and 460 years (n ¼ 18). The three groups did not differ with respect to time from diagnosis to transplantation, Lille score or peripheral blood counts at the time of transplantation. Probability of OS at 5 years was about 75% for the two groups of patients with age up to 60 years, whereas the corresponding figure for the patients 460 years of age was 20%. The difference was highly significant (P ¼ 0.003) ( Figure 2 ). As no MAC patient was older than 60 years, the corresponding analyses could not be made for this patient group.
In total, 37 patients had a sibling donor, 10 had a related non-sibling and 45 had a matched unrelated donor (MUD). The survival for these three different groups was not significantly different (P ¼ 0.921).
When the transplanted patients were grouped with respect to Lille score, the probability of OS at 5 years for 18 patients with score 0 was 70%, for the 41 patients with score 1 was 59% and for the 31 patients with score 2 was 41%. The difference between the groups was not statistically significant (P ¼ 0.082).
The stem cell source for the patients in the MAC-treated group was BM in 14 cases, PBSC in 24 and a combination of BM and PBSC in 2 cases. The probability of OS was not significantly influenced by the type of stem cell source (P ¼ 0.826).
Out of 40, 6 MAC-treated patients had a MF post-ET or post-PV, compared with 16 of the 52 patients in the RIC group, but this difference was not statistically significant (P ¼ 0.090). The difference in survival between PMF and secondary MF did not reach statistical significance (P ¼ 0.852). 
Causes of death
Data are shown in detail in Table 4 . In total, 38 patients have died after transplantation during the study time, 22 in the MAC group after a mean time of 17.4 (range 0-133) months after transplantation compared with 16 patients in the RIC group after a mean time of 21.8 (1-102) months. Early deaths, that is, within 3 months after transplantation, were reported in 7 patients out of the 40 treated with MAC; four had organ failure, one had lung bleeding, one had GVHD and one had progressive disease. Out of 52, 3 RICtreated patients died within 3 months; two had infectious complications and one had organ failure. Thus, the TRM at 3 months from transplantation was 15% in the MAC group compared with 5.8% for the RIC-treated patients, but the difference between the groups did not reach statistical significance (P ¼ 0.170).
The causes of deaths related to transplantation, up to 2 years, for the patients treated with MAC and RIC were: organ failure (n ¼ 9 and 2), infection (n ¼ 2 and 5), major bleeding (n ¼ 2 and 1), GVHD (n ¼ 2 and 2) and unknown reason (n ¼ 1 and 0). The TRM at 2 years, for the patients transplanted at least 24 months before the end of the study, was 32 and 24% for the MAC and RIC-treated patients, respectively. The difference did not reach statistical significance (P ¼ 0.623). In addition, three patients treated with MAC and four with RIC died within 2 years because of relapse or progression of MF.
Six transplanted patients died after 24 months or more from the time of transplantation. The causes of death were progressive disease, non-hematological malignancy, cGVHD and infection for the MAC-treated patients, and two cases of non-hematological cancer and one GVHD among the RIC patients.
Additional donor stem cell or lymphocyte infusion Out of 92, 11 patients received DLI at 2-26 months from transplantation. All of these patients were transplanted with RIC. The reason for DLI treatment for two patients was recipient chimerism, and for the remaining nine patients mixed chimerism. Four of the patients who received DLI died after a time of 4 to 17 months. Relapse was the cause of death in three patients, and organ failure in the fourth. Seven of the 11 DLI-treated patients were alive at the end of the study and most of them were in CR.
Three of the patients who received MAC also had a reinfusion of stem cells without conditioning at 3-4 months from transplantation because of engraftment failure. One of these patients was found dead in his home at 8 months after transplantation; the cause of death was unknown. Two patients were alive at 42 and 87 months after transplantation, respectively.
Eight patients, two in the MAC group and six in the RIC group, required a second transplantation. The reasons were graft failure, progress of the MF or transformation into AML. Three of the eight patients were alive at the end of the study (6, 19 and 83 months after the second transplantation), whereas five patients had died at 1-8 months after the second transplantation.
Discussion
During the last decade, transplantation with RIC has been introduced, 16 and several studies have shown that this procedure has made it possible to offer allo-SCT to an older group of patients. 7, 17 The present study summarizes the outcome for the complete number of MF patients in chronic phase transplanted at the nine centers in the Nordic countries, that is, 92 patients.
The survival after allo-SCT in MF seems highly correlated to the age at the time of transplantation, a result also reported by others. 18, 19 Thus, if the patients were divided into groups below or over the median age at transplantation, 53 years, the younger RIC-treated patients had a significantly better survival compared with the older patients (P ¼ 0.003). When adjustment for differences in age was carried out, survival in the RIC-treated group was found superior (hazard ratio was 3.58 with 95% confidence interval 1.54-8.28, P ¼ 0.003). Further, we found a significantly poorer survival among the RIC-treated patients over the age of 60 years compared with patients below this age (P ¼ 0.003). The probability of OS at 5 years was close to 80% for the two groups of patients with age up to 60 years, whereas the corresponding figure for the patients 460 years of age was 20% (Figure 2) . The difference in OS between MAC-treated patients below and above the median transplant age of 53 years was 52 vs 39%, but did not reach statistical significance. There was no difference between the patients in the different age groups with regard to time from diagnosis to transplantation, Lille score or peripheral blood values at the time of transplantation. Owing to lack of pertinent data in the EBMT registry, it was not possible to compare comorbidity in this study, but it is likely that the screening investigation before transplantation had identified patients with significant heart or pulmonary disorders. The probability of survival for the MF patients transplanted with either RIC or MAC in our study was at least as good as for patients transplanted because of AML or MDS. Thus, McClune et al. 18 reported a 2-year survival of 44% for AML patients at 40-54 years of age and 36% for the patient group over 65 years. In Table 4 Causes of death in patients receiving allo-transplantation between 1982 and 2009 for myelofibrosis, reported to the EBMT another study presented by Hemmati et al., 19 AML patients transplanted with RIC had a probability of 5-year survival of 61% compared with 56% for MAC-treated patients. In comparison between RIC and MAC, several background factors must be taken into consideration. The RIC patients were 9-years older (mean), which should mean a worse survival. On the other hand, supportive care may have been more effective during the last decade, when all the RIC patients were transplanted. Another difference was that 16 of the RIC patients had post-PV/ET MF compared with 6 in the MAC group. However, no difference in OS was found when the PMF patients and post-ET/PV patients were compared (P ¼ 0.852). BM stem cells were used in 40% of the MAC-treated patients compared with 2% in the RIC-treated group. No survival differences were found when the MAC-treated patients, given BM or PBSC, were compared (P ¼ 0.826).
Out of the differences between the groups, the age, according to our own results, should be the most important, and therefore should affect RIC results negatively. The only two differences between RIC and MAC that reached statistical significance were aGVHD (less in RIC) and the use of DLI (more in RIC). However, several other variables showed numerical differences. TRM at 100 days (5.8 vs 17.5%) and at 2 years (24 vs 32%), as well as OS at 5 years (49 vs 59%) showed better figures for RIC. The TRM in the present study was comparable with other reports: Kroger et al.
20 0% and Merup et al. 7 10% for RICtreated patients, and 18-35% for patients transplanted with either RIC or MAC reported in the recent study by Ballen et al. 21 Ballen et al. 21 reported a probability of OS at 5 years of 30-40%, depending on type of donor.
Evaluation of GVHD could only be made at the time of 3 months after transplantation, as the registration frequency in the EBMT database, later in the course, was found to be insufficient. The organ most frequently affected by GVHD was the skin for both patients transplanted with RIC and MAC. Frequencies and grade are reported in Table 2 . In the MAC group, 24% of the patients were reported to have no GVHD, compared with 72% in the RIC group (Po0.001). The frequency of grade II-IV GVHD in the MAC group, 34%, is well in accordance with other reports. 21 Even as GVHD was only reported as the cause of death in six cases, three in the MAC group and three in the RIC group, it is likely to be a contributing cause of the numerical differences in early TRM.
The majority of the patients in the present study were transplanted with PBSC. In only 14 of the patients (all in the MAC group), BM was the only stem cell source, and in the RIC group only 1. The type of stem cells used did not affect TRM at 100 days or affect probability of long-term survival. There was not any significant effect on OS (P ¼ 0.826 in the MAC group). Therefore, it is not likely that the difference in stem cell source between the MAC and RIC groups affected the results. Further, the type of stem cell donor, that is, sibling, matched unrelated donor or matched related donor other than sibling, did not affect the outcome. This finding supports the results reported in several other studies. 7, 20 In one recent study, 21 the donor type had a significant influence on survival; both the whole group of patients and RIC-transplanted patients had poorer outcome with matched unrelated donor. One explanation to these differences is that the latter study reports 7 out of 60 patients with non-ablative treatment with engraftment failure who all died, whereas we had no reported engraftment failure in our cohort of RIC-treated patients.
Previous reports have shown a favorable outcome for patients with MF transplanted early in the course of the disease and with more favorable prognostic score. 12, 22 This was also the case in the present study, when adjustment for age differences was carried out in patients with higher Lille score had an inferior survival (hazard ratio 1.67, with 95% confidence interval 1.03-2.72, P ¼ 0.038). In our study, International Working Group score did not show significant prognostic value (P ¼ 0.604). Even if patients with Lille score 2 have a worse survival after BMT than patients with less advanced disease, these high-risk patients may be the ones that are most likely to benefit most from allo-transplantation, as their mean survival is only 13 months with conventional care. 9 When considering the potential benefit from allo-SCT for patients with Lille score 0, one may compare the predicted survival in Dupriez's study 9 of 7.8 years, including the 50% of patients above the age where transplantation is not advisable, with the 'low-risk' group in our study with a probability of OS at 10 years of 70%.
A total of 38 out of the 92 patients died during the study time. Organ failure, including acute respiratory distress syndrome, was the most common cause of death in the MAC group, whereas infections were most frequent among the RIC-treated patients. Only eight patients (9%), four patients in each group, were reported dead because of relapse, progressive disease or transformation into AML. The pattern of transplant-related complications did not differ significantly from that of allo-SCT for other diagnoses. Infection, mostly bacterial or viral, was a major problem, CMV reactivation occurred in 16 patients, and 5 patients had a fatal disseminated aspergillosis. A fairly high incidence of major bleeding was recorded, 13 cases, including 3 fatal. One may speculate that the MPN origin of MF gives rise to megakaryocyte and/or platelet morbidity-facilitating bleeding.
DLI was significantly more often needed as treatment for the RIC-transplanted patients. Eleven patients in the RIC group compared with none in the MAC group were given DLI, 2-26 months from transplantation (P ¼ 0.002). However, three patients in the MAC group had a reinfusion of stem cells given, without conditioning, because of engraftment failure. The reason for DLI infusion was recipient chimerism in two patients and mixed chimerism in the remaining nine patients. Eight patients were transplanted a second time, two in the MAC group and six in the RIC group. The difference between the groups was NS (P ¼ 0.458). The reason for a second transplant was graft failure, progression of MF or transformation into AML. Three of these eight patients were alive at the end of the study, whereas five patients died at 1-8 months from the second transplant.
In conclusion, the present study summarizes the outcome of the total number of 92 patients with MF in chronic phase that underwent allo-SCT in nine Nordic transplant centers between 1982 and 2009. Age was found to have a major influence on the outcome, whereas the conditioning type and the source of donor cells did not. RIC-treated patients had a significantly better OS compared with MACtreated patients, when adjustment for age differences was made. As in previous studies, survival was worse in patients with more advanced disease; a higher Lille score was related with shorter survival. DLI was used more often in the RIC group, but graft failure was only found in the MAC group (three cases). Survival and TRM were comparable to those in SCT for AML.
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